期刊
CHEMELECTROCHEM
卷 6, 期 4, 页码 989-1003出版社
WILEY-V C H VERLAG GMBH
DOI: 10.1002/celc.201800848
关键词
Biosensor; cancer; clinical diagnostics; electrochemical impedance spectroscopy; oncomarkers
资金
- Slovak Scientific Grant Agency VEGA [2/0137/18, 2/0090/16]
- Slovak Research and Development Agency [APVV 17-0300, APVV-15-0227]
- European Research Council [311532]
- ERDF [26240120007]
- European Research Council (ERC) [311532] Funding Source: European Research Council (ERC)
Impedimetric affinity biosensors are, without any doubt, among the most sensitive analytical devices available, offering low limits of detection and wide linear response ranges. There are, however, only a few papers detailing the application of impedimetric biosensors for the analysis of clinically relevant samples with due clinical performance. The fact that these devices have not found their way to any commercial or clinical use to date might be surprising, since an electrochemical assay platform based on portable potentiostats is a success story for monitoring a range of clinical parameters such as ions, haematological indicators and glucose. This review discusses the reasons behind this discrepancy and addresses the barriers to be overcome in order to achieve the point-of-care diagnostics using such devices for detection of protein oncomarkers approved by FDA. The final part of the review covers the most recent progress in the area.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据